Intensive Outpatient Prolonged Exposure for Combat-Related PTSD: A Case Study

The prevalence rates for combat-related posttraumatic stress disorder (PTSD) in U.S. military personnel returning from deployments to Iraq and Afghanistan indicate a significant demand for efficacious treatments that can be delivered in military-relevant formats. According to research with civilian and veteran populations, prolonged exposure is a first-line treatment for PTSD. However, research examining the generalizibility of prolonged exposure to active-duty military service members is scarce. Modifications to the standard prolonged exposure protocol may be required to meet military operational needs and to circumvent unique treatment barriers associated with the military. Intensive outpatient or compressed treatment delivered over a short time period has the potential for significant operational utility for active-duty military populations. Intensive outpatient practice formats have been found to be efficacious for the treatment of other anxiety disorders (i.e., specific phobia, obsessive-compulsive disorder). The present case report is the first to evaluate the use of intensive outpatient prolonged exposure for combat-related PTSD in an active-duty military service member. Treatment consisted of 10 full-day outpatient sessions over a 2-week period. The patient’s PTSD, depression, and anxiety were dramatically reduced by the end of treatment, and she no longer met diagnostic criteria for PTSD. She remained in full remission at the 6-month follow-up

Evaluation of a Brief Marriage Intervention for Internal Behavioral Health Consultants in Military Primary Care

Military couples face significant challenges to their relationships including demanding schedules, multiple deployments, and frequent moves. Despite the high costs of chronic marital distress, very few military (or civilian) couples seek marriage therapy. The military services and the VA system have implemented collaborative care models in primary care where internal behavioral health consultants are integrated into primary care. Integrated primary care can reduce the stigma of behavioral health services and may increase the odds that couples would seek help earlier. There are no established couple interventions designed for use in primary care. The purpose of this presentation is to describe a program of research focused on adapting and validating The Marriage Checkup (MC) for use in an integrated primary care clinic.https://corescholar.libraries.wright.edu/urop_celebration/1019/thumbnail.jp

Cibler l’addiction transcriptionnelle dans le mélanome cutané

Malgré de récentes avancées thérapeutiques révolutionnaires, le mélanome métastatique constitue toujours un problème de santé publique important, caractérisé par l'émergence rapide de sous-populations cellulaires résistantes aux traitements. Les cellules de mélanome se distinguent des cellules normales par une caractéristique associée au cancer que l'on peut cibler. En effet, les cellules de mélanome présentent un état de ‘dépendance transcriptionnelle’, par lequel elles deviennent dépendantes de l'expression intense d'oncogènes clés. Nous cherchons ici à déterminer si l'utilisation d'inhibiteurs de la transcription pourrait constituer une stratégie efficace de traitement du mélanome. Nous constatons qu’un inhibiteur de CDK7, THZ1, n'affecte pas tous les types de cellules de mélanome de la même manière et qu'une inhibition prolongée de CDK7 conduit à des cellules de mélanome plus dédifférenciées, plus invasives et plus résistantes aux traitements. Cependant, l'inhibition de XPB, un partenaire moléculaire de CDK7, ne provoque pas un tel changement de phénotype et cible efficacement l'expression des gènes oncogènes, ce qui justifie des études plus approfondies. En outre, nous établissons que l'utilisation de la Lurbinectedine et de ses dérivés structuraux pourrait être bénéfique sur le plan clinique dans le mélanome, mais nous élucidons également pour la première fois des mécanismes de résistance potentiels contre ce nouveau type d'inhibiteur transcriptionnel. En conclusion, ce travail met en lumière des questions fondamentales concernant la régulation de l'expression des gènes dans les cellules de mélanome et leurs réponses moléculaires et cellulaires aux inhibiteurs de la transcription, tout en élucidant leurs avantages et inconvénients cliniques potentiels pour les patients.Despite revolutionary recent advances in therapeutics, metastatic melanoma still poses a significant public health problem, characterized by rapidly emerging treatment-resistant cell subpopulations. In a fashion distinguishing them from normal cells and representing thus a targetable cancer-associated hallmark, melanoma cells display a state of ‘transcriptional addiction’, by which they become dependent on the intense expression of key oncogenes. Here, we elucidate whether the use of transcriptional inhibitors might be a useful addition to the existing framework of melanoma treatments. We find that the CDK7 inhibitor THZ1 does not affect all melanoma cell types equally, and that prolonged CDK7 inhibition leads to melanoma cells becoming more dedifferentiated, invasive and treatment-resistant. However, the inhibition of XPB, a molecular partner of CDK7, does not elicit such a phenotype switch, and potently targets oncogenic gene expression, thus warranting more extensive studies. Furthermore, we establish that the use of Lurbinectedin and its structural derivatives might be of clinical benefit in melanoma, but also elucidate for the first time potential resistance mechanisms against this new type of transcriptional inhibitors. In conclusion, this work sheds light on fundamental questions concerning gene expression regulation in melanoma cells and their molecular and cellular responses to transcriptional inhibitors, while also elucidating their potential clinical patient-related benefits and shortcomings

Cibler l’addiction transcriptionnelle dans le mélanome cutané

Despite revolutionary recent advances in therapeutics, metastatic melanoma still poses a significant public health problem, characterized by rapidly emerging treatment-resistant cell subpopulations. In a fashion distinguishing them from normal cells and representing thus a targetable cancer-associated hallmark, melanoma cells display a state of ‘transcriptional addiction’, by which they become dependent on the intense expression of key oncogenes. Here, we elucidate whether the use of transcriptional inhibitors might be a useful addition to the existing framework of melanoma treatments. We find that the CDK7 inhibitor THZ1 does not affect all melanoma cell types equally, and that prolonged CDK7 inhibition leads to melanoma cells becoming more dedifferentiated, invasive and treatment-resistant. However, the inhibition of XPB, a molecular partner of CDK7, does not elicit such a phenotype switch, and potently targets oncogenic gene expression, thus warranting more extensive studies. Furthermore, we establish that the use of Lurbinectedin and its structural derivatives might be of clinical benefit in melanoma, but also elucidate for the first time potential resistance mechanisms against this new type of transcriptional inhibitors. In conclusion, this work sheds light on fundamental questions concerning gene expression regulation in melanoma cells and their molecular and cellular responses to transcriptional inhibitors, while also elucidating their potential clinical patient-related benefits and shortcomings.Malgré de récentes avancées thérapeutiques révolutionnaires, le mélanome métastatique constitue toujours un problème de santé publique important, caractérisé par l'émergence rapide de sous-populations cellulaires résistantes aux traitements. Les cellules de mélanome se distinguent des cellules normales par une caractéristique associée au cancer que l'on peut cibler. En effet, les cellules de mélanome présentent un état de ‘dépendance transcriptionnelle’, par lequel elles deviennent dépendantes de l'expression intense d'oncogènes clés. Nous cherchons ici à déterminer si l'utilisation d'inhibiteurs de la transcription pourrait constituer une stratégie efficace de traitement du mélanome. Nous constatons qu’un inhibiteur de CDK7, THZ1, n'affecte pas tous les types de cellules de mélanome de la même manière et qu'une inhibition prolongée de CDK7 conduit à des cellules de mélanome plus dédifférenciées, plus invasives et plus résistantes aux traitements. Cependant, l'inhibition de XPB, un partenaire moléculaire de CDK7, ne provoque pas un tel changement de phénotype et cible efficacement l'expression des gènes oncogènes, ce qui justifie des études plus approfondies. En outre, nous établissons que l'utilisation de la Lurbinectedine et de ses dérivés structuraux pourrait être bénéfique sur le plan clinique dans le mélanome, mais nous élucidons également pour la première fois des mécanismes de résistance potentiels contre ce nouveau type d'inhibiteur transcriptionnel. En conclusion, ce travail met en lumière des questions fondamentales concernant la régulation de l'expression des gènes dans les cellules de mélanome et leurs réponses moléculaires et cellulaires aux inhibiteurs de la transcription, tout en élucidant leurs avantages et inconvénients cliniques potentiels pour les patients

Senior Show 2020 079

This exhibition, which was featured in the Robert and Elaine Stein Galleries at Wright State University, featuring works by the senior class of 2007. This exhibition ran from April 1 to May 2, 2020, featuring works of from a variety of artists in various mediums.https://corescholar.libraries.wright.edu/restein_exhibitions_all/1482/thumbnail.jp